ASCIA News

ASCIA News

• Thunderstorm asthma epidemic

  Dec 9, 2016:  The recent thunderstorm asthma epidemic in Melbourne and its tragic consequences highlight the need for more research, education and awareness in this area. Thunderstorm asthma is thought to be triggered by thunderstorms that have rapid changes in wind, temperature and humidity, which cause pollen grains to absorb moist...

• ASCIA highlights from 2016 and plans for 2017

  Nov 28, 2016:  As the end of 2016 approaches it is timely to reflect on the significant development, achievements and collaborations of ASCIA over the past year, and plans for 2017. Thank you to ASCIA members and supporters for your greatly appreciated contributions throughout 2016.  We look forward to continuing to work wi...

• Allergy and Immunology Foundation of Australasia (AIFA) Research Grants

  Nov 16, 2016:  AIFA has provided $100,000 in research grants to support 6 projects over the past 3 years. This funding includes two $10,000 grants announced this month, one supporting research into Jack Jumper Ant immunotherapy and the second that will improve development of a drug for allergy. For information about these grants go ...

• AusPollen Apps for people with allergic rhinitis (hay fever) and allergic asthma

  Nov 8, 2016:  Local AusPollen Apps provide information on daily levels of pollen in the air and are currently available for Brisbane, Canberra, Melbourne and Sydney at http://ift.tt/2iVezlV downloading the free App for iTunes or Google Play, and through Twitter or Facebook. Completion of a short (~5 minute) online questio...

• National Allergy Strategy - KABAM survey

  Nov 3, 2016:  THANK YOU to all who participated in the National Allergy Strategy survey for teens and young adults (KABAM survey). The response has been overwhelming and we look forward to reviewing the information to ensure we develop suitable resources for 12-24 year olds with severe allergy. Stay tuned for updates on resource devel...

• ASCIA 2016 Conference Report

  Sep 21, 2016:  The ASCIA 2016 conference provided more than 600 delegates with a unique opportunity to hear from 6 international experts and more than 30 local experts on a wide range of areas in allergy and clinical immunology. The conference also included 79 posters, 48 poster presentations and 16 clinical grand rounds presentations...

• AIFA seed funding leads to NHMRC grant

  Aug 23, 2016:  We are proud to announce that the AusPollen project has been awarded $626,442 in the latest round of NHMRC Partnership Project grants with a further $653,129 in partner organisation in kind and cash support. AusPollen, the Australian Pollen Allergen Partnership, will build, implement and evaluate the first standardised ...

• Updated ASCIA Action Plans for Anaphylaxis and Allergic Reactions

  Aug 10, 2016:  ASCIA has released updated Action Plans for Anaphylaxis and Allergic Reactions on its website: http://ift.tt/1yS3Z48 The main changes are an increased emphasis of key messages, inclusion of images to show how to position a person with anaphylaxi...

• ASCIA releases guidelines for infant feeding and allergy prevention

  May 18, 2016: ASCIA Guidelines for infant feeding and allergy prevention and information on how to introduce solid foods to infants have been released on the ASCIA website: http://ift.tt/2jILsWY These guidelines provide parents and health professionals with advice and recommendations relevant to...

• Federal Government announces funding of $500k for National Allergy Strategy implementation

  May 16, 2016:  It is with great pleasure that we confirm that the federal government's funding of $500k for National Allergy Strategy implementation was announced at the launch of Food Allergy Week in Sydney on 16 May 2016, by the Minister for Health, the Hon Sussan Ley MP. The National Allergy Strategy was launched in...

• Changes to adrenaline autoinjector labels

  Apr 19 2016:  In Australia, adrenaline is the approved name of the ingredient in autoinjector devices used for the emergency treatment of anaphylaxis. Currently, the only available autoinjector to treat anaphylaxis in Australia and New Zealand is supplied under the brand name EpiPen®. In some countries, including the USA, adrenaline i...

http://ift.tt/2iVi2B0